Do peptides help female hair thinning after menopause?

The short answer

Evidence tier: 2 — RCTs and Cochrane review for minoxidil; tier 3–4 for every peptide.

No peptide has been shown in a randomised trial to treat female hair thinning after menopause. The peptide hair studies in women are small, often industry-run, usually mix men and women, and often test the peptide alongside other actives. Most of the GHK-Cu hair data comes from lab cells and hair follicles grown in dishes.

What does have evidence in women: topical minoxidil is the only FDA-approved treatment for female pattern hair loss, and 5% foam is licensed for once-daily use in women. Low-dose oral minoxidil and spironolactone are used off-label, with smaller trials behind them.

Before any of that, the type of shedding matters. Pattern loss, stress shedding, postpartum shedding and GLP-1-related shedding need different approaches. Thyroid and iron checks are a standard part of the workup.

The key points:

• Female pattern hair loss affects nearly half of women in their lifetime, and the risk rises after menopause.
• A 404-woman phase III trial found once-daily 5% minoxidil foam added about 9 hairs/cm² over placebo at 24 weeks.
• GHK-Cu hair evidence is mostly in vitro. The one positive placebo-controlled trial used a GHK combination in men, and a 2026 eyebrow study had 18 participants.
• Biotinoyl tripeptide-1, acetyl tetrapeptide-3 and PTD-DBM have, at best, small mixed-sex or combination studies. PTD-DBM has only been tested in mice and lab tissue.
• GLP-1 drugs are linked to shedding that usually works like telogen effluvium.

What kind of hair loss is it?

Evidence tier: 2 — clinical reviews and diagnostic guidance.

"Thinning" covers several conditions with different causes and outlooks:

• Female pattern hair loss (FPHL), or androgenetic alopecia. Gradual widening of the part and thinning over the crown, usually with the front hairline kept. Follicles shrink over successive cycles. It affects nearly 50% of women during their lifetime. Falling estrogen at menopause may remove some protection (Kearney 2026).
• Telogen effluvium (TE). Sudden, diffuse shedding, typically 2–4 months after a trigger such as illness, surgery, crash dieting, a new medicine or iron deficiency. It often settles once the trigger is removed. Chronic TE can look like FPHL and needs to be ruled out (Kearney 2026).
• Postpartum shedding. A form of TE after childbirth. It can unmask underlying FPHL that was already developing (Galal 2024). The women's minoxidil label tells users not to use it if hair loss is linked to childbirth (label).
• GLP-1-associated shedding. Seen in about 3–5% of patients in pivotal trials, mainly as TE from rapid weight loss and low intake (Bridges 2026). In a 2026 BMJ study of adults with type 2 diabetes, GLP-1 drugs carried a higher risk of non-scarring hair loss than SGLT-2 or DPP-4 inhibitors, though absolute risk was low (Tang 2026). More in does Ozempic cause hair loss.

Patchy loss, scalp pain, redness or scarring point to other diagnoses such as alopecia areata or scarring alopecia. These need a dermatologist.

Which tests are usually part of the workup?

Evidence tier: 2 — clinical reviews and specialist guidance.

A 2026 review of hair loss evaluation lists thyroid-stimulating hormone (TSH), a full blood count and iron studies as the recommended baseline tests (Walker 2026).

Iron and ferritin. Ferritin confirms iron deficiency but can read falsely high with inflammation. After menopause, iron deficiency is more often due to gastrointestinal blood loss or poor absorption than to menstruation, so a low result should be investigated, not just supplemented (Trost 2006). That review also found insufficient evidence for routine iron supplements in hair loss without anaemia, so this decision belongs with a physician.

Hormones. An expert committee recommends assessing every woman with FPHL for possible androgen excess (acne, excess facial hair, irregular cycles before menopause), with hormone tests guided by the findings (Carmina 2019).

For what to test and when if you are already using peptides, see labs before and during peptides.

What has proven evidence for women?

Evidence tier: 1 — regulator label, phase III RCT and Cochrane review.

This section explains why peptides get compared against minoxidil. It is not a recommendation to use any of these treatments.

Topical minoxidil

• A Cochrane review of 47 trials (5,290 women) found topical minoxidil effective for FPHL, with no clear difference between 2% and 5% (van Zuuren 2016).
• In a phase III trial of 404 women, 5% foam once daily added 9.1 hairs/cm² over vehicle at 24 weeks. Scalp irritation and unwanted facial hair were uncommon (Bergfeld 2016).
• The US label specifies once-daily application. Results may take 3–6 months, and the product may be harmful during pregnancy or breastfeeding (label).

Off-label options

• Low-dose oral minoxidil. In a randomised trial of 52 women, oral 1 mg was compared with topical 5% over 24 weeks, and hair density rose in both groups (Ramos 2020). It is a blood-pressure drug, so it needs medical supervision. See oral minoxidil evidence.
• Spironolactone. A meta-analysis reported improvement in about 57% of women, but the studies were mixed and of variable quality (Aleissa 2023). A 2025 JAAD review discusses when anti-androgens are considered and their contraindications (Ong 2025).
• Finasteride 1 mg did not beat placebo in the Cochrane analysis (van Zuuren 2016).

Whether any of these suit a particular woman depends on her blood pressure, other medicines and cancer history. That is a conversation for a physician.

Does GHK-Cu help female hair thinning?

Evidence tier: 4 — mostly in vitro and ex vivo; human studies small, in men, or on eyebrows.

What exists:

• Lab studies. A related copper peptide (AHK-Cu) lengthened human hair follicles grown in dishes and showed signs of reducing dermal papilla cell death, though that change was not statistically significant (Pyo 2007).
• One placebo-controlled scalp trial, in men. A GHK–aminolevulinic acid complex increased hair count over 6 months in 45 men with pattern loss. Hair thickness did not change (Lee 2016). GHK was combined with another active, and no women were enrolled.
• Eyebrows. A 2026 randomised split-face study of 18 people reported more and thicker eyebrow hairs with a 2% GHK-Cu serum at 12 weeks. It was published in a regional proceedings journal and summarised in Mateescu 2026, which noted the study did not confirm how much intact GHK-Cu was delivered.
• Cosmetic scalp study. An open-label 15-day trial of a scrub plus a copper tripeptide-1 serum targeted dandruff. It reported higher "hair density" on imaging, but it had no control group, used several actives, and was run with the manufacturer (Patel 2024).

No published RCT has tested GHK-Cu alone for FPHL in women.

Does copper peptide plus microneedling work better?

Evidence tier: 4 — case series and mechanistic reasoning.

Microneedling has its own trial evidence. Combined with minoxidil it improved hair counts in a randomised pilot in men (Dhurat 2013), possibly by increasing the scalp enzymes that activate minoxidil (Sharma 2020).

Adding copper peptide to needling rests on very little. A four-patient case series used laser-assisted delivery of a mix of finasteride, growth factors and 1% copper peptide, so the copper peptide's contribution can't be separated out (Bertin 2018). A 2026 systematic review found that microneedle-delivered GHK-Cu has not been tested in a single registered, adequately powered human RCT (Najafi 2026).

Needling also opens the skin to whatever is in the serum, which raises the stakes for contamination and irritation. See GHK-Cu microneedling for hair for the technique questions.

What about Procapil, Capixyl and PTD-DBM?

Evidence tier: 3–4 — small, mixed-sex, combination or animal studies, often commercially linked.

Supplier-run "in vivo studies" in ingredient brochures are not peer-reviewed. They usually test small groups over short periods without a placebo, so treat them as marketing.

Even trials in older women can be hard to use. A 2026 open-label study of a two-serum cosmetic system in mostly menopausal women reported less shedding at 4 months, but it had no control group and was tied to the brand (Fernández 2026). For non-peptide alternatives, see minoxidil-free hair serums.

How is this different from male-focused hair advice?

Evidence tier: 2 — sex-specific trial findings.

• Finasteride, a mainstay for men, did not beat placebo for women in pooled trials (van Zuuren 2016). It can also harm a male fetus, which matters before menopause.
• The pattern differs. Women usually keep their hairline and thin diffusely over the crown, which makes TE and FPHL easier to confuse.
• Most peptide hair studies enrol men or mixed groups and don't report results for women separately.

Our general peptides for hair loss review covers the male-skewed data in more depth.

Limitations of the evidence

Evidence tier: 3–4 — summary of the evidence gaps above.

• Peptide hair studies are small, short and often industry-run, and several have no placebo or control group.
• Most enrol men or mixed groups and don't report results for women separately.
• Peptides are usually tested alongside other actives, so their own effect can't be separated out.
• GHK-Cu hair data are mostly from lab cells and follicles; PTD-DBM has only mouse and tissue data.
• Supplier "in vivo studies" are not peer-reviewed.

The bottom line

After menopause, the hair-loss treatments with real evidence for women are minoxidil (topical approved, oral off-label) and, for some women, anti-androgens. Peptides such as GHK-Cu, biotinoyl tripeptide-1 and acetyl tetrapeptide-3 have early or commercially driven data that doesn't show benefit for women specifically. Getting the diagnosis right, including thyroid and iron checks, matters more than which serum you pick. Treatment decisions belong with a dermatologist or physician.

Related on this site

• Peptides for hair loss: the evidence in 2026
• Does Ozempic cause hair loss?
• Oral minoxidil for hair loss: the evidence
• GHK-Cu and microneedling for hair
• Peptides in perimenopause and menopause
• Labs before and during peptides
• Peptides for women: the 2026 cornerstone

References

• Kearney CA et al. Androgenetic alopecia in women: a narrative review of pathophysiology, clinical evaluation, and treatments. Am J Clin Dermatol 2026 — topical minoxidil the only FDA-approved option for FPHL. PMID 41714473
• van Zuuren EJ et al. Interventions for female pattern hair loss. Cochrane Database Syst Rev 2016 — 47 RCTs; minoxidil effective; finasteride not. PMID 27225981
• Bergfeld W et al. A phase III, multicenter, parallel-design clinical trial to compare the efficacy and safety of 5% minoxidil foam versus vehicle in women with female pattern hair loss. J Drugs Dermatol 2016 — 404 women, 24 weeks. PMID 27391639
• Ramos PM et al. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: a randomized clinical trial. J Am Acad Dermatol 2020 — 52 women. PMID 31473295
• Aleissa M. The efficacy and safety of oral spironolactone in the treatment of female pattern hair loss: a systematic review and meta-analysis. Cureus 2023 — heterogeneous evidence. PMID 37719557
• Ong MM et al. Antiandrogen therapy for the treatment of female pattern hair loss. J Am Acad Dermatol 2025 — clinical review. PMID 40345536
• Walker CW et al. Hair loss: a systematic approach to evaluation, diagnosis, and management. JAAPA 2026 — TSH, CBC, iron studies recommended. PMID 42647672
• Trost LB et al. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol 2006 — ferritin interpretation; causes after menopause. PMID 16635664
• Carmina E et al. Female pattern hair loss and androgen excess. J Clin Endocrinol Metab 2019 — Androgen Excess and PCOS Society committee report. PMID 30785992
• Galal SA et al. Postpartum telogen effluvium unmasking additional latent hair loss disorders. J Clin Aesthet Dermatol 2024. PMID 38779373
• Bridges AG, Jackson T. Hair and scalp effects of GLP-1 receptor agonists in practice. Clin Dermatol 2026 — 3–5% incidence; mainly TE. PMID 42767469
• Tang H et al. Risk of hair loss associated with GLP-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ 2026 — observational. PMID 42486607
• Pyo HK et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res 2007 — ex vivo follicles. PMID 17703734
• Lee WJ et al. Efficacy of a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide on hair growth. Ann Dermatol 2016 — placebo-controlled, 45 men. PMID 27489425
• Mateescu DM et al. GHK-Cu as a bioactive metallopeptide and drug-delivery cargo. Pharmaceutics 2026 — evidence map including the 2026 eyebrow RCT. PMID 42797253
• Patel MN et al. A novel scalp treatment regimen combining a hydroxy acid-based scrub and copper tripeptide serum in seborrheic dermatitis. Cureus 2024 — open-label, manufacturer-linked. PMID 39449909
• Najafi N et al. Systematic review of GHK-Cu in topical microneedle delivery. Arch Intern Med Res 2026 — no adequately powered human RCT. PMID 42787770
• Dhurat R et al. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia. Int J Trichology 2013 — men. PMID 23960389
• Sharma A et al. Microneedling improves minoxidil response by upregulating follicular sulfotransferase enzymes. J Biol Regul Homeost Agents 2020. PMID 32492993
• Bertin ACJ et al. Fractional non-ablative laser-assisted drug delivery leads to improvement in male and female pattern hair loss. J Cosmet Laser Ther 2018 — 4 cases. PMID 29452017
• Khoso H, Fahim M. Comparison of PRP alone with PRP along with daily topical 5% Procapil for androgenetic alopecia. J Ayub Med Coll Abbottabad 2024 — quasi-experimental. PMID 39609969
• Samadi A et al. Topical formulation containing caffeine and Procapil 3% for male pattern hair loss. J Cosmet Dermatol 2024 — men. PMID 37990760
• Lueangarun S, Panchaprateep R. Biochanin A, acetyl tetrapeptide-3 and ginseng extracts versus 3% minoxidil for androgenetic alopecia. J Clin Aesthet Dermatol 2020 — 32-person RCT. PMID 33584955
• Lee SH et al. Targeting of CXXC5 by a competing peptide stimulates hair regrowth and wound-induced hair neogenesis. J Invest Dermatol 2017 — mouse and tissue data (PTD-DBM). PMID 28595998
• Fernández DG et al. Efficacy of a dual-serum cosmetic system in women with female pattern hair loss. J Drugs Dermatol 2026 — open-label, brand-linked. PMID 42235052
• Women's minoxidil 5% foam — US Drug Facts label. — once-daily use; childbirth-related loss exclusion. ndclist.com